Scarica l'app Stockscreener
14.31
0.92%
0.124
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARQT Giù?
Forum
Previsione
Precedente Chiudi:
$14.19
Aprire:
$14.22
Volume 24 ore:
500.24K
Relative Volume:
0.28
Capitalizzazione di mercato:
$1.72B
Reddito:
$59.61M
Utile/perdita netta:
$-262.14M
Rapporto P/E:
-3.6515
EPS:
-3.92
Flusso di cassa netto:
$-247.49M
1 W Prestazione:
-6.56%
1M Prestazione:
-4.60%
6M Prestazione:
+8.40%
1 anno Prestazione:
+50.90%
Intervallo 1D:
$14.08
$14.37
Intervallo di 1 settimana:
$13.70
$16.39
Portata 52W:
$8.03
$17.75
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Nome
Arcutis Biotherapeutics Inc
Settore
Industria
Telefono
805-418-5006
Indirizzo
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Confronta ARQT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
14.32 | 1.77B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
382.00 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.89 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.39 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
641.87 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.35 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Iniziato | Goldman | Neutral |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-26 | Downgrade | Mizuho | Buy → Neutral |
| 2023-10-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-09-07 | Iniziato | Needham | Buy |
| 2022-03-17 | Iniziato | Goldman | Buy |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-05-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-10-08 | Iniziato | Truist | Buy |
| 2020-02-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Iniziato | Cowen | Outperform |
| 2020-02-25 | Iniziato | Goldman | Neutral |
| 2020-02-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie
Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year? - Yahoo Finance
Arcutis outlines sustained ZORYVE growth with 28% sequential revenue expansion and eyes cash flow breakeven in 2026 - MSN
Arcutis Biotherapeutics Awards Restricted Stock Units to New Employees Under Nasdaq Listing Rule 5635(c)(4) - AInvest
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics Grants $1.2M in Equity Awards to Strategic New Hires in Dermatology Push - Stock Titan
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q2 2025 Earnings Call Transcript - Insider Monkey
Analysts Weigh In on GoodRx Holdings (GDRX) and Arcutis Biotherapeutics (ARQT) - AInvest
Arcutis Biotherapeutics Receives Buy Rating and $21.00 Price Target from Morgan Stanley - AInvest
Arcutis Biotherapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates - MSN
A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $21 to $25 - 富途牛牛
Seborrhoeic Dermatitis Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Arcutis Biotherapeutics, Cutanea Life Sciences, Moberg Pharma AB, Astion Pharma A/S, LEO Pharma - Barchart.com
Earnings call transcript: Arcutis Q2 2025 beats EPS and revenue forecasts - Investing.com
Arcutis' Path to Profitability and Market Leadership in Dermatology - AInvest
Arcutis Biotherapeutics: Scaling ZORYVE Foam to Redefine Psoriasis Treatment and Drive Sustainable Growth - AInvest
Transcript : Arcutis Biotherapeutics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Arcutis Biotherapeutics Reports Strong Q2 2025 Growth - TipRanks
Arcutis (ARQT) Q2 Revenue Soars 164% - The Globe and Mail
Arcutis Biotherapeutics: Strong Performance and Growth Potential Drive Buy Rating - TipRanks
Seborrhea Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Arcutis Biotherapeutics, Cutanea Life Sciences Inc., Vyome Therapeutics - Barchart.com
Molluscum Contagiosum Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Arcutis Biotherapeutics, Asana BioSciences - Barchart.com
Arcutis Q2 2025 slides: Revenue soars 164% YoY as portfolio expansion drives growth - Investing.com Australia
Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Earnings Flash (ARQT) Arcutis Biotherapeutics, Inc. Reports Q2 Revenue $81.5M, vs. FactSet Est of $73.7M - MarketScreener
Top Executives Sell Significant Shares of Arcutis Biotherapeutics! - TipRanks
Arcutis Biotherapeutics director Welgus sells $142,982 in shares By Investing.com - Investing.com Nigeria
Matsuda Masaru sells Arcutis Biotherapeutics (ARQT) shares for $90,687 By Investing.com - Investing.com Australia
Matsuda Masaru sells Arcutis Biotherapeutics (ARQT) shares for $90,687 - Investing.com India
Arcutis Biotherapeutics director Welgus sells $142,982 in shares - Investing.com India
Arcutis Biotherapeutics director Watanabe sells $165k in shares By Investing.com - Investing.com Canada
Hand Eczema Clinical Trials, Companies, Therapeutic - openPR.com
Arcutis Biotherapeutics Inc (ARQT) Q2 2025: Everything You Need to Know Ahead of Earnings - GuruFocus
Seborrhoeic Dermatitis Clinical Trials, Companies, - openPR.com
Seborrhoeic Dermatitis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Arcutis Biotherapeutics, Cutanea Life Sciences, DermBiont, Astion Pharma - Barchart.com
What is the dividend policy of Arcutis Biotherapeutics Inc. stockMaximize your portfolio’s growth potential - Jammu Links News
How many analysts rate Arcutis Biotherapeutics Inc. as a “Buy”Discover investment plans that deliver results - Jammu Links News
What analysts say about Arcutis Biotherapeutics Inc. stockTrack top-performing stocks effortlessly - Jammu Links News
How volatile is Arcutis Biotherapeutics Inc. stock compared to the marketOutstanding capital growth - Jammu Links News
When is Arcutis Biotherapeutics Inc. stock expected to show significant growthMaximize your portfolio’s earning power - Jammu Links News
What institutional investors are buying Arcutis Biotherapeutics Inc. stockCapitalize on momentum-driven opportunities - Jammu Links News
What are the technical indicators suggesting about Arcutis Biotherapeutics Inc.Discover undervalued opportunities early - Jammu Links News
What catalysts could drive Arcutis Biotherapeutics Inc. stock higher in 2025Free High-Return Strategy Alerts - Jammu Links News
Published on: 2025-08-03 10:58:14 - Jammu Links News
Is Arcutis Biotherapeutics Inc. a growth stock or a value stockDouble or triple returns - Jammu Links News
What is Arcutis Biotherapeutics Inc. company’s growth strategyBuild a diversified portfolio for risk management - Jammu Links News
What are the latest earnings results for Arcutis Biotherapeutics Inc.Consistently high yield - Jammu Links News
How does Arcutis Biotherapeutics Inc. compare to its industry peersChart Pattern Planner For Fast Growth - Jammu Links News
Arcutis Biotherapeutics (ARQT): A High-Growth Play in Immuno-Dermatology Driven by ZORYVE's Expanded Access and Long-Term Efficacy - AInvest
Arcutis: Leveraging Zoryve’s Success While Positioning For Pipeline Expansion (ARQT) - Seeking Alpha
Analysts Expect Arcutis Biotherapeutics to Report Q2 Earnings of $0.18 per Share, Revenues of $72.57M - AInvest
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Arcutis Biotherapeutics Inc Azioni (ARQT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.40%
2.78%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):